Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV.

Ana González-CordónLambert AssoumouGraeme MoyleLaura WatersMargaret JohnsonPere DomingoJulie FoxHans-Jürgen StellbrinkGiovanni Guaraldi Mar MasiáMark GompelsStephane De WitEric FlorenceStefan EsserFrançois RaffiGeorg BehrensAnton PozniakJosé M GatellEsteban Martíneznull null

Published in: The Journal of antimicrobial chemotherapy (2021)

Switching from boosted PIs to dolutegravir in PLWH with high cardiovascular risk led to soluble CD14 and adiponectin reductions at 48 weeks. While decreasing soluble CD14 may entail favourable health effects in PLWH, adiponectin reduction may reflect less insulin sensitivity associated with weight gain.

Keyphrases

weight gain
metabolic syndrome
insulin resistance
body mass index
birth weight
hiv infected patients
antiretroviral therapy
weight loss